Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

543
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
543
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

218
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
218
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

403
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
403
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

266
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
266
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

186
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
186
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of intranasal esketamine in the treatment of patients with treatment-resistant depression: an observational study based on data collected in a Spravato treatment program at the Institute of Living, Hartford, CT.

Psychopharmacology·2026
Same author

From Misophonia Through Puberphonia: Window Toward Gender Dysphoria in Autism?

Autism research : official journal of the International Society for Autism Research·2025
Same author

Robotic-assisted super-extended pelvic lymph node dissection for prostate cancer: safety and pathologic findings.

The Canadian journal of urology·2025
Same author

Implementation and Integration of a Hospital-Wide Postpartum Hypertension Clinic.

Women's health reports (New Rochelle, N.Y.)·2025
Same author

Discovery of ancestry-specific variants associated with clopidogrel response among Caribbean Hispanics.

NPJ genomic medicine·2025
Same author

Transperineal Magnetic Resonance Imaging-Fusion Targeted Prostate Biopsy Utilizing the PrecisionPoint Transperineal Access System vs a Grid Template: An Assessment of Outcomes.

Urology·2025

Related Experiment Video

Updated: Nov 19, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.1K

Subanalysis of the CYP-GUIDES Trial: CYP2D6 Functional Stratification and Operational Timeline Selection.

Gualberto Ruaño1, Joseph Tortora2, Saskia Robinson2

  • 1Institute of Living at Hartford Hospital, 67 Jefferson Street, Hartford, CT 06106, United States; Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT, United States.

Psychiatry Research
|January 29, 2021
PubMed
Summary
This summary is machine-generated.

Pharmacogenetic testing using CYP2D6 genotype guided treatment for major depressive disorder significantly reduced hospital Length of Stay (LOS) in patients with subfunctional CYP2D6 status. This approach also decreased the prescription of CYP2D6 substrate drugs.

Keywords:
CYP2D6 pharmacogeneticsclinical decision supportmajor depressive disorderpsychiatric hospitalizationpsychotropic utilization

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.2K
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.7K

Related Experiment Videos

Last Updated: Nov 19, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.1K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.2K
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.7K

Area of Science:

  • Pharmacogenomics
  • Clinical Decision Support
  • Psychiatry

Background:

  • Major depressive disorder (MDD) treatment is complex, with variable patient responses to psychotropic medications.
  • Cytochrome P450 2D6 (CYP2D6) genotype influences drug metabolism and efficacy.
  • Personalized medicine approaches, including pharmacogenetics, aim to optimize MDD treatment outcomes.

Purpose of the Study:

  • To evaluate the impact of CYP2D6 genotype-guided psychotropic therapy on clinical outcomes in hospitalized MDD patients.
  • To assess the effect of CYP2D6 functional status on Length of Stay (LOS) and Re-Admission Rate (RAR).
  • To present a subanalysis examining the influence of CYP2D6 stratification on LOS.

Main Methods:

  • Randomized Controlled Trial (RCT) comparing CYP2D6 genotype-guided treatment versus standard care.
  • Analysis of primary outcome (LOS) and secondary outcome (30-day RAR).
  • Subanalysis isolating confounders: Electronic Medical Record, minimum 3-day LOS, and CYP2D6 functional stratification.

Main Results:

  • CYP2D6 functional stratification allowed subgroup comparison within guided (Group G) and standard (Group S) treatment arms.
  • Subfunctional CYP2D6 patients in Group G experienced a 2-day shorter LOS compared to Group S.
  • Subfunctional patients in Group S received a higher percentage and number of CYP2D6 substrate psychotropic prescriptions.

Conclusions:

  • Pharmacogenetic clinical decision support, specifically CYP2D6 genotyping, effectively reduced LOS in patients with subfunctional CYP2D6 status.
  • This approach also led to a reduction in the prescribing of CYP2D6 substrate-dependent drugs.
  • Genotype-guided therapy offers a personalized strategy to improve treatment efficiency and reduce medication burden in MDD.